Format

Send to

Choose Destination
Expert Rev Hematol. 2014 Jun;7(3):373-85. doi: 10.1586/17474086.2014.899896. Epub 2014 Apr 10.

Factor VIII therapy for hemophilia A: current and future issues.

Author information

1
Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1006, Newyork, NY, USA.

Abstract

Hemophilia A is a congenital, recessive, X-linked bleeding disorder that is managed with infusions of plasma-derived or recombinant factor (F) VIII. The primary considerations in FVIII replacement therapy today are the: 1) immunogenicity of FVIII concentrates, 2) role of longer-acting FVIII products, 3) prophylactic use of FVIII in children and adults with severe hemophilia A, and 4) affordability and availability of FVIII products. Improving patient outcomes by increasing the use of FVIII prophylaxis, preventing or eliminating FVIII inhibitors, and expanding access to FVIII concentrates in developing countries are the major challenges confronting clinicians who care for patients with hemophilia A.

KEYWORDS:

FVIII; factor concentrate; gene therapy; genetics; hemophilia A; immunogenicity; longer-acting FVIII; prophylaxis

PMID:
24717090
DOI:
10.1586/17474086.2014.899896
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center